Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab maintenance in advanced penile cancer
NCT03774901Phase 2Unknown
- Sponsor
- CHU de Besançon
- Start
- Mar 2019
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in squamous cell carcinoma of the penis (SCCP), sponsored by CHU de Besançon. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
avelumab
03
Conditions
squamous cell carcinoma of the penis (SCCP)
Beyond the preview
Go deeper on NCT03774901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774901.